January 19, 2006. Novartis reported positive data from a Phase III trial of its hypertension therapy; Dynavax said its allergy drug Tolamba did well in a two-year Phase II/III trial; Omrix Biopharmaceuticals, which makes biosurgical and passive immunotherapy products, filed for its IPO; GTx Inc said its prostate cancer drug passed its interim safety review;Neurobiological Technologies received another $5 million for the sale of Xerecept; and Medarex announced that its 29th antibody has reached clinical development. The Centient Biotech 200? moved another 8 points higher to 4055.01, a rise of .20%. More details...
